Home Tags Dolaflexin

Tag: dolaflexin

Mersana Therapeutics Focuses its Resources on Advancing XMT-1536, its First-in-Class ADC...

Mersana Therapeutics, a clinical-stage biopharmaceutical company developing a pipeline of antibody-drug conjugates or ADCs designed to target cancers in areas of high unmet need,...

XMT-1522 Trial in Progress Data Presented at ASCO

Data from a trials in progress abstract presented during the 2017 annual meeting of the American Society of Clinical Oncology (ASCO) confirmed the continued...

XMT-1536 Demonstrates Anti-Cancer Activity in Patients with NaPi2b-expressing Tumors

Preclinical data for Mersana Therapeutics' new immunoconjugate product candidate, XMT-1536, demonstrated significant anti-cancer activity in non-small cell lung cancer (NSCLC) and ovarian cancer tumor models. The...

XMT-1522 Continues to Demonstrate Complete Tumor Regressions in Multiple HER2-Expressing Breast...

Positive preclinical data for Mersana Therapeutics'  lead product candidate, XMT-1522, demonstrates significant anti-cancer activity in both HER2-positive and HER2 low-expressing tumor models refractory to...

DOWNLOAD